A Phase I/II Study of the Combination of Panobinostat and Carfilzomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Final Analysis of Second Dose Expansion

被引：0
|
作者：
Berdeja, Jesus G. [1 ,2 ]
Gregory, Tara B. [1 ,3 ]
Faber, Edward [1 ,4 ]
Matous, Jeffrey [1 ,3 ]
Hart, Lowell [1 ,5 ]
Mace, Joseph R. [1 ,6 ]
Arrowsmith, Edward R. [1 ,7 ]
Flinn, Ian W. [1 ,2 ]
机构：
[1] Sarah Cannon Res Inst, Nashville, TN USA
[2] Tennessee Oncol PLLC, Nashville, TN USA
[3] Colorado Blood Canc Inst, Denver, CO USA
[4] Oncol Hematol Care Inc, Cincinnati, OH USA
[5] Florida Canc Specialists, Ft Myers, FL USA
[6] Florida Canc Specialists, St Petersburg, FL USA
[7] Tennessee Oncol PLLC, Chattanooga, TN USA
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.4530.4530
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4530
引用
收藏
页数：6
相关论文
共 50 条
  • [41] Carfilzomib for the treatment of patients with relapsed and/or refractory multiple myeloma
    Stewart, A. Keith
    FUTURE ONCOLOGY, 2015, 11 (15) : 2121 - 2136
  • [42] IKEMA: Carfilzomib as the preferred combination with isatuximab in relapsed or refractory multiple myeloma patients?
    Cailly, Laura
    Leleu, Xavier
    Gruchet, Cecile
    HEMATOLOGIE, 2021, 27 (05): : 217 - 218
  • [43] A phase 1/2 study of carfilzomib in Japanese patients with relapsed and/or refractory multiple myeloma
    Watanabe, Takashi
    Tobinai, Kensei
    Matsumoto, Morio
    Suzuki, Kenshi
    Sunami, Kazutaka
    Ishida, Tadao
    Ando, Kiyoshi
    Chou, Takaaki
    Ozaki, Shuji
    Taniwaki, Masafumi
    Uike, Naokuni
    Shibayama, Hirohiko
    Hatake, Kiyohiko
    Izutsu, Koji
    Ishikawa, Takayuki
    Shumiya, Yoshihisa
    Kashihara, Tomohisa
    Iida, Shinsuke
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 172 (05) : 745 - 756
  • [44] A phase 1 study of filanesib, carfilzomib, and dexamethasone in patients with relapsed and/or refractory multiple myeloma
    Hans C. Lee
    Jatin J. Shah
    Lei Feng
    Elisabet E. Manasanch
    Rebecca Lu
    Ashley Morphey
    Brandon Crumpton
    Krina K. Patel
    Michael L. Wang
    Raymond Alexanian
    Sheeba K. Thomas
    Donna M. Weber
    Robert Z. Orlowski
    Blood Cancer Journal, 9
  • [45] A phase 1 study of filanesib, carfilzomib, and dexamethasone in patients with relapsed and/or refractory multiple myeloma
    Lee, Hans C.
    Shah, Jatin J.
    Feng, Lei
    Manasanch, Elisabet E.
    Lu, Rebecca
    Morphey, Ashley
    Crumpton, Brandon
    Patel, Krina K.
    Wang, Michael L.
    Alexanian, Raymond
    Thomas, Sheeba K.
    Weber, Donna M.
    Orlowski, Robert Z.
    BLOOD CANCER JOURNAL, 2019, 9 (10)
  • [46] Recapturing Disease Response: A Phase II Study of High Dose Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma Who Have Progressed on Standard Dose Carfilzomib
    Chari, Ajai
    Cho, Hearn Jay
    Parekh, Samir
    Osman, Keren
    Goldstein, Talia
    Morgan, Gillian
    La, Lisa
    Carter, Crystle
    Catamero, Donna
    Escalon, Juliet
    Verina, Daniel
    Florendo, Erika
    Yum, Moon-hee
    Stevens, Nadege
    Gullie, Jude
    Chan, Elaine
    Jagannath, Sundar
    BLOOD, 2015, 126 (23)
  • [47] Final Results of the Phase I/II Study of Chemosensitization Using the CXCR4 Inhibitor Plerixafor in Combination with Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma
    Ghobrial, Irene M.
    Shain, Kenneth H.
    Laubach, Jacob
    Henrick, Patrick
    Vredenburg, James
    Crilley, Pamela
    Constantine, Michael
    Block, Caroline
    Basile, Frank G.
    Cappuccio, Joseph
    Azab, Abdel Kareem
    Lai, Emily
    Caola, Aaron
    Banwait, Ranjit
    Savell, Alexandra
    Munshi, Nikhil C.
    Paba-Prada, Claudia E.
    Schlossman, Robert L.
    Chuma, Stacey
    Noonan, Kimberly
    Anderson, Kenneth C.
    Richardson, Paul G.
    BLOOD, 2015, 126 (23)
  • [48] A Phase I/II Study of Bortezomib (VELCADE) in Combination with Pralatrexate in Relapsed/Refractory Multiple Myeloma
    Dunn, Tamara J.
    Dinner, Shira N.
    Berube, Caroline
    Gotlib, Jason
    Coutre, Steven E.
    Medeiros, Bruno C.
    Liedtke, Michaela
    BLOOD, 2012, 120 (21)
  • [49] CARFILZOMIB, BENDAMUSTINE AND DEXAMETHASONE (CBD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: RESULTS OF A PHASE I/II EMN STUDY
    Offidani, M.
    Guenther, A.
    Gay, F.
    Engelhardt, M.
    Gentili, S.
    Montefusco, V.
    Patriarca, F.
    Angelucci, E.
    Schub, N.
    Astolfi, M.
    Poenisch, W.
    Einsele, H.
    Sonneveld, P.
    Boccadoro, M.
    Corradini, P.
    Gramatzki, M.
    HAEMATOLOGICA, 2017, 102 : 37 - 37
  • [50] A study of carfilzomib and dexamethasone in patients with relapsed and refractory multiple myeloma in China
    Juan Du
    Baijun Fang
    Jian Li
    Jie Jin
    Shunqing Wang
    Dehui Zou
    Zhen Cai
    Hongxiang Wang
    Jianda Hu
    Wei Li
    Chengcheng Fu
    Zonghong Shao
    Zhongjun Xia
    Peng Liu
    Ting Niu
    En-Tzu Tang
    Amy S. Kimball
    Jian Hou
    Wenming Chen
    International Journal of Hematology, 2021, 113 : 422 - 429
12345